Cell Discovery (Dec 2022)
COVID-19 vaccination boosts the potency and breadth of the immune response against SARS-CoV-2 among recovered patients in Wuhan
- Hong Liang,
- Xuanxuan Nian,
- Junzheng Wu,
- Dong Liu,
- Lu Feng,
- Jia Lu,
- Yan Peng,
- Zhijun Zhou,
- Tao Deng,
- Jing Liu,
- Deming Ji,
- Ran Qiu,
- Lianzhen Lin,
- Yan Zeng,
- Fei Xia,
- Yong Hu,
- Taojing Li,
- Kai Duan,
- Xinguo Li,
- Zejun Wang,
- Yong Zhang,
- Hang Zhang,
- Chen Zhu,
- Shang Wang,
- Xiao Wu,
- Xiang Wang,
- Yuwei Li,
- Shihe Huang,
- Min Mao,
- Huanhuan Guo,
- Yunkai Yang,
- Rui Jia,
- Jingwei Xufang,
- Xuewei Wang,
- Shuyan Liang,
- Zhixin Qiu,
- Juan Zhang,
- Yaling Ding,
- Chunyan Li,
- Jin Zhang,
- Daoxing Fu,
- Yanlin He,
- Dongbo Zhou,
- Cesheng Li,
- Jiayou Zhang,
- Ding Yu,
- Xiao-Ming Yang
Affiliations
- Hong Liang
- Beijing Tiantan Biological Products Co., Ltd.
- Xuanxuan Nian
- National Engineering Technology Research Center for Combined Vaccines
- Junzheng Wu
- Chengdu Rongsheng Pharmaceuticals Co., Ltd.
- Dong Liu
- Beijing Tiantan Biological Products Co., Ltd.
- Lu Feng
- Sinopharm Wuhan Plasma-derived Biotherapies Co., Ltd.
- Jia Lu
- National Engineering Technology Research Center for Combined Vaccines
- Yan Peng
- Sinopharm Wuhan Plasma-derived Biotherapies Co., Ltd.
- Zhijun Zhou
- Sinopharm Wuhan Plasma-derived Biotherapies Co., Ltd.
- Tao Deng
- National Engineering Technology Research Center for Combined Vaccines
- Jing Liu
- National Engineering Technology Research Center for Combined Vaccines
- Deming Ji
- Sinopharm Wuhan Plasma-derived Biotherapies Co., Ltd.
- Ran Qiu
- National Engineering Technology Research Center for Combined Vaccines
- Lianzhen Lin
- Sinopharm Wuhan Plasma-derived Biotherapies Co., Ltd.
- Yan Zeng
- National Engineering Technology Research Center for Combined Vaccines
- Fei Xia
- National Engineering Technology Research Center for Combined Vaccines
- Yong Hu
- Sinopharm Wuhan Plasma-derived Biotherapies Co., Ltd.
- Taojing Li
- Beijing Tiantan Biological Products Co., Ltd.
- Kai Duan
- National Engineering Technology Research Center for Combined Vaccines
- Xinguo Li
- National Engineering Technology Research Center for Combined Vaccines
- Zejun Wang
- National Engineering Technology Research Center for Combined Vaccines
- Yong Zhang
- Beijing Tiantan Biological Products Co., Ltd.
- Hang Zhang
- Beijing Tiantan Biological Products Co., Ltd.
- Chen Zhu
- Sinopharm Wuhan Plasma-derived Biotherapies Co., Ltd.
- Shang Wang
- Sinopharm Wuhan Plasma-derived Biotherapies Co., Ltd.
- Xiao Wu
- Sinopharm Wuhan Plasma-derived Biotherapies Co., Ltd.
- Xiang Wang
- National Engineering Technology Research Center for Combined Vaccines
- Yuwei Li
- National Engineering Technology Research Center for Combined Vaccines
- Shihe Huang
- National Engineering Technology Research Center for Combined Vaccines
- Min Mao
- Sinopharm Wuhan Plasma-derived Biotherapies Co., Ltd.
- Huanhuan Guo
- Wuxue Wusheng Plasma Collection Center
- Yunkai Yang
- China National Biotec Group Company Limited
- Rui Jia
- China National Biotec Group Company Limited
- Jingwei Xufang
- China National Biotec Group Company Limited
- Xuewei Wang
- China National Biotec Group Company Limited
- Shuyan Liang
- Wuhan Biobank Co., Ltd.
- Zhixin Qiu
- Wuhan Biobank Co., Ltd.
- Juan Zhang
- Wuhan Biobank Co., Ltd.
- Yaling Ding
- Chengdu Rongsheng Pharmaceuticals Co., Ltd.
- Chunyan Li
- Beijing Tiantan Biological Products Co., Ltd.
- Jin Zhang
- Sinopharm Wuhan Plasma-derived Biotherapies Co., Ltd.
- Daoxing Fu
- Beijing Tiantan Biological Products Co., Ltd.
- Yanlin He
- Beijing Tiantan Biological Products Co., Ltd.
- Dongbo Zhou
- Beijing Tiantan Biological Products Co., Ltd.
- Cesheng Li
- Sinopharm Wuhan Plasma-derived Biotherapies Co., Ltd.
- Jiayou Zhang
- National Engineering Technology Research Center for Combined Vaccines
- Ding Yu
- Beijing Tiantan Biological Products Co., Ltd.
- Xiao-Ming Yang
- National Engineering Technology Research Center for Combined Vaccines
- DOI
- https://doi.org/10.1038/s41421-022-00496-x
- Journal volume & issue
-
Vol. 8,
no. 1
pp. 1 – 14
Abstract
Abstract The immunity of patients who recover from coronavirus disease 2019 (COVID-19) could be long lasting but persist at a lower level. Thus, recovered patients still need to be vaccinated to prevent reinfection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or its mutated variants. Here, we report that the inactivated COVID-19 vaccine can stimulate immunity in recovered patients to maintain high levels of anti-receptor-binding domain (RBD) and anti-nucleocapsid protein (NP) antibody titers within 9 months, and high neutralizing activity against the prototype, Delta, and Omicron strains was observed. Nevertheless, the antibody response decreased over time, and the Omicron variant exhibited more pronounced resistance to neutralization than the prototype and Delta strains. Moreover, the intensity of the SARS-CoV-2-specific CD4+ T cell response was also increased in recovered patients who received COVID-19 vaccines. Overall, the repeated antigen exposure provided by inactivated COVID-19 vaccination greatly boosted both the potency and breadth of the humoral and cellular immune responses against SARS-CoV-2, effectively protecting recovered individuals from reinfection by circulating SARS-CoV-2 and its variants.